- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
The AGPR Index - novel non-invasive marker in Chronic Hepatitis B
Researchers from China developed a novel, simple, accurate, and noninvasive marker to predict Liver Fibrosis and Cirrhosis in Chronic Hepatitis B patients. The research was published in the "World Journal of Gastroenterology, 2022."
Hepatitis B virus affects human health in varied ways. It can cause fibrosis and cirrhosis of the liver leading to Hepatocellular Carcinoma. Due to its considerable necessity, researchers from China conducted a study to develop a Non-invasive, practical, and convenient means of predicting liver fibrosis and cirrhosis.
As Liver biopsy is the gold standard, they established a new index with parameters like alkaline phosphatase(U/L) + gamma-glutamyl transpeptidase (U/L)/platelet (109/L) (AGPR) to predict liver fibrosis and cirrhosis. Along with this they also compared the area under the receiver operating characteristic curve (AUROC) of AGPR, gamma-glutamyl transpeptidase to platelet ratio, aspartate transaminase to platelet ratio index, and FIB-4 and evaluated the accuracy of these routine laboratory indices in predicting liver fibrosis and cirrhosis.
Results:
- Correlation analysis revealed a significant positive correlation between AGPR and liver fibrosis stage (P < 0.001).
- In the training cohort, the AUROC of AGPR was 0.83 for predicting fibrosis (≥ F2), 0.84 for predicting extensive fibrosis (≥ F3), and 0.87 for predicting cirrhosis (F4).
- In the validation cohort, the AUROCs of AGPR to predict ≥ F2, ≥ F3, and F4 were 0.83, 0.83, and 0.84, respectively.
Thus, the researchers concluded that for the prediction of liver fibrosis and cirrhosis in Chronic Hepatitis B patients, the novel AGPR index should be used as it is a simple, accurate and noninvasive marker.
To read the full article, click here: 10.3748/wjg.v28.i27.3503
Liao MJ, Li J, Dang W, Chen DB, Qin WY, Chen P, Zhao BG, Ren LY, Xu TF, Chen HS, Liao WJ. Novel index for the prediction of significant liver fibrosis and cirrhosis in chronic hepatitis B patients in China. World J Gastroenterol 2022; 28(27): 3503-3513.
BDS, MDS
Dr.Niharika Harsha B (BDS,MDS) completed her BDS from Govt Dental College, Hyderabad and MDS from Dr.NTR University of health sciences(Now Kaloji Rao University). She has 4 years of private dental practice and worked for 2 years as Consultant Oral Radiologist at a Dental Imaging Centre in Hyderabad. She worked as Research Assistant and scientific writer in the development of Oral Anti cancer screening device with her seniors. She has a deep intriguing wish in writing highly engaging, captivating and informative medical content for a wider audience. She can be contacted at editorial@medicaldialogues.in.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751